Select Medical Holdings Corporation vs Synopsys, Inc. — how do they compare? Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B), while Synopsys, Inc. trades at $388.58 (market cap $72.47B). The key difference: Synopsys, Inc. is far larger — about 35.4× Select Medical Holdings Corporation's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SEM | SNPS | |
|---|---|---|
Market Cap | $2.05B | $72.47B |
Sector | Health | Technology |
52-Week High | $16.66 | $645.59 |
52-Week Low | $11.77 | $378.46 |
Enterprise Value | $5.01B | $80.82B |
Dividend Yield | 1.51% | — |
Signals from Pluang's Aura AI — not financial advice
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported 2025 revenue of $5.45 billion with a net income margin of 2.42%, while valuation ratios like a P/E of 15.43 and P/S of 0.36 appear reasonable. Recent earnings show two misses in the last three quarters against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the $16.50 deal price. Risks include ongoing shareholder litigation alleging fiduciary breaches by the board regarding the buyout fairness. Analyst sentiment is neutral with a Hold-heavy consensus, while the stock's future price action will largely hinge on legal outcomes surrounding the acquisition terms rather than operational performance.
No Aura AI signal available yet.
Trailing returns across standard periods
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →